Background: Polycythemia vera (PV) and chronic lymphocytic leukemia (CLL) are distinct hematological malignancies. While their coexistence is rare, it poses unique diagnostic and therapeutic challenges.
Methods: A 50-year-old male patient presented with elevated hemoglobin levels and a marked lymphocytosis. Diagnostic investigations revealed the presence of both PV and CLL. The patient received treatment for PV followed by CLL.
Results: Initial treatment with hydroxyurea for PV led to progression of CLL. Subsequent treatment with rituximab and venetoclax effectively managed CLL, although the JAK2V617F mutation re-emerged.
Conclusions: This case highlights the potential for independent origins of myeloid and lymphoid neoplasms. Further research is needed to understand the interplay between these two malignancies and optimize their management.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.7754/Clin.Lab.2024.240925 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Thrombosis-Driven Disease Progression in JAK2-Mutant Polycythemia Vera and Essential Thrombocythemia: Reassessing Risk-Based Management.
Am J Hematol
March 2025
CRIMM, Azienda Ospedaliera Universitaria Careggi, Dipartimento di Medicina Sperimentale e Clinica, Università di Firenze, Florence, Italy.
This paper explores emerging therapies in polycythemia vera and essential thrombocythemia, focusing on thrombosis as a driver of disease progression leading to myelofibrosis, blast phase, second cancers, and mortality. While the thrombosis rate in high-risk patients has declined, it remains persistently high in low-risk individuals, with most events being arterial. Inflammation driven by JAK2 V617F mutation plays a primary role in pathogenesis, and mounting evidence suggests arterial thrombosis itself can fuel a self-sustaining cycle of inflammation, thereby accelerating hematologic and systemic complications.
View Article and Find Full Text PDFLong-term survival for myeloid neoplasms and national health expenditure: A EUROCARE-6 retrospective, population-based study.
Eur J Cancer
January 2025
Analytical Epidemiology and Health Impact Unit, Department of Epidemiology and Data Science, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Background: EUROCARE, a European population-based cancer project, has shown geographical survival disparities for myeloid neoplasms (MN) suggesting healthcare inequalities. Total National Health Expenditure (TNHE) might influence population-based MN survival. We studied the long-term survival of 15 MN and the TNHE impact on prognosis between European countries.
View Article and Find Full Text PDFRegression of Left Ventricular Hypertrophy After Polycythemia Vera Treatment With Incidental Finding of Unicuspid Aortic Valve.
JACC Case Rep
March 2025
Department of Cardiology, Ascension St. Vincent Hospital, Indianapolis, Indiana, USA.
We present a unique case of a 38-year-old man with 2 rare conditions: unicuspid aortic valve and polycythemia vera. The patient developed left ventricular hypertrophy, which showed regression after polycythemia vera treatment. This is the first reported case of left ventricular hypertrophy regression after polycythemia vera treatment.
View Article and Find Full Text PDFArticle Synopsis
- ECLIPSE-PV is a randomized, multicenter clinical trial that evaluates the efficacy and safety of two different dosing regimens of ropeginterferon alfa-2b-njft (ropeg) for treating polycythemia vera (PV), a blood disorder.
- The study compares the standard approved dosing regimen of ropeg, which typically starts at 100 or 50 μg and increases gradually, with a higher initial dose and faster titration (HIDAT regimen) starting at 250 μg and escalating quickly to 500 μg if tolerated.
- The primary goal is to measure the complete hematologic response rate at 24 weeks, with additional focuses on safety, molecular responsiveness, and quality of
A Toolkit for Healthcare Transition for Adolescents With Classical Myeloproliferative Neoplasms.
Pediatr Blood Cancer
March 2025
Hôpital Saint Louis, Paris, France.
Classical myeloproliferative neoplasms (MPNs) are being identified more frequently in adolescents. There is no guidance on the healthcare transition of young MPN patients from pediatric to adult medicine. Therefore, we convened an international panel of experts in both pediatric and adult MPN care to develop three tools to facilitate high-quality healthcare transition: a physician education tool, a transition readiness assessment tool, and a consensus statement of practice recommendations to ensure a more seamless transition in the care adolescents receive.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!